YFP Rab4DN
(Plasmid
#99019)
-
PurposeLocalization and visualization of the dominant negative form of Rab4
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 99019 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerinvitrogen
- Backbone size w/o insert (bp) 5428
- Total vector size (bp) 6790
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameRab4 DN
-
SpeciesD. melanogaster (fly), Synthetic
-
Insert Size (bp)789
-
MutationS22N Dominant negative
-
GenBank IDNM_166240.3
-
Entrez GeneRab4 (a.k.a. Dmel_CG4921, CG 4921, CG4921, DRAB4, DmRab4, Dmel\CG4921, Q7KY04, RAB4c, rab4)
- Promoter CMV
-
Tag
/ Fusion Protein
- YFP (N terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NheI (not destroyed)
- 3′ cloning site NotI (not destroyed)
- 5′ sequencing primer T7
- 3′ sequencing primer BGH (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byMatthew Scott Addgene #37691
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
YFP Rab4DN from Addgene 37691 was transferred to pcDNA3.1
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
YFP Rab4DN was a gift from Narasimhan Gautam (Addgene plasmid # 99019 ; http://n2t.net/addgene:99019 ; RRID:Addgene_99019) -
For your References section:
Membrane Flow Drives an Adhesion-Independent Amoeboid Cell Migration Mode. O'Neill PR, Castillo-Badillo JA, Meshik X, Kalyanaraman V, Melgarejo K, Gautam N. Dev Cell. 2018 Jun 15. pii: S1534-5807(18)30422-2. doi: 10.1016/j.devcel.2018.05.029. 10.1016/j.devcel.2018.05.029 PubMed 29937389